Selected ongoing upfront trials of immunotherapy in lymphoma
| Trial ID . | Study regimen . | Phase . | Study objective(s) . |
|---|---|---|---|
| NCT03274492 | Polatuzumab with R-CHP vs R-CHOP in previously untreated DLBCL | III13 | Primary end point: investigator-assessed PFS |
| Secondary end points: IRC-assessed PET/CT CR rate at EOT, EFS, 2-y PFS, and OS | |||
| NCT03907488 | BV vs nivolumab plus AVD in newly diagnosed stage III-IV cHL | III | Primary end point: PFS |
| Secondary end points: OS, EFS, CR rate, and TRAE rate |
| Trial ID . | Study regimen . | Phase . | Study objective(s) . |
|---|---|---|---|
| NCT03274492 | Polatuzumab with R-CHP vs R-CHOP in previously untreated DLBCL | III13 | Primary end point: investigator-assessed PFS |
| Secondary end points: IRC-assessed PET/CT CR rate at EOT, EFS, 2-y PFS, and OS | |||
| NCT03907488 | BV vs nivolumab plus AVD in newly diagnosed stage III-IV cHL | III | Primary end point: PFS |
| Secondary end points: OS, EFS, CR rate, and TRAE rate |
AVD, doxorubicin- vinblastine-dacarbazine; BV, brentuximab vedotin; cHL, classical Hodgkin lymphoma; CR, complete response; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival; EOT, end of treatment; IRC, independent review committee; OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone; R-CHP, rituximab-cyclophosphamide-doxorubicin-prednisone; TRAE, treatment-related adverse event.